NASDAQ:COYA Coya Therapeutics Q3 2026 Earnings Results & Report $3.18 -0.15 (-4.35%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Coya Therapeutics missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.45 versus the -$0.35 consensus estimate, while revenue of $234.13 thousand topped the $110 thousand estimate by $124.13 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call8:00 AM ET Coya Therapeutics EPS ResultsActual EPS-$0.45Consensus EPS -$0.35Beat/MissMissed by -$0.10One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCoya Therapeutics Revenue ResultsActual Revenue$234.13 thousandExpected Revenue$110 thousandBeat/MissBeat by +$124.13 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Coya Therapeutics Q3 2026 Earnings FAQ Did Coya Therapeutics beat earnings estimates for Q3 2026? Coya Therapeutics (NASDAQ:COYA) reported earnings of -$0.45 per share for Q3 2026, missing the consensus estimate of -$0.35. The report was announced on Tuesday, November 10, 2026. What was Coya Therapeutics' revenue for Q3 2026? Coya Therapeutics reported revenue of $234.13 thousand for Q3 2026, against a consensus estimate of $110 thousand. Coya Therapeutics Earnings HeadlinesCoya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateNovember 10 at 8:32 AM | finance.yahoo.comCoya Therapeutics (COYA) Expected to Announce Quarterly Earnings on WednesdayNovember 10 at 2:57 AM | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Coya Therapeutics, Inc. (COYA) - What Are Investment Firms Thinking About This Stock?November 9 at 2:59 AM | americanbankingnews.comAnalyzing Coya Therapeutics (COYA) and Its RivalsNovember 2, 2026 | americanbankingnews.comCoya Therapeutics, Inc. Presents Neurofilament Light Chain Biomarker Stratification Methodology in the Alstars Trial At the 2026 Annual Neals MeetingOctober 28, 2026 | marketscreener.comMSee More Coya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coya Therapeutics and other key companies, straight to your email. Email Address About Coya TherapeuticsCoya Therapeutics (NASDAQ:COYA) is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company's lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient's own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered. Coya is also developing additional Treg-based and combination therapies for ALS and potentially other neurodegenerative diseases. Coya Therapeutics was founded in 2020 and is headquartered in Houston, Texas. Its development programs are investigational and subject to clinical testing and regulatory review; the company has not established that its therapies are safe or effective for any approved indication.View Coya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
